HeartSciences, a Fierce Innovation Award Finalist, Will Present at BioTech Showcase Events in San Francisco on January 9 and 10, 2018

SOUTHLAKE, Texas-Thursday, January 4th 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- HeartSciences, a medical device company recently selected as a finalist for the Fierce Innovation Awards in the Digital Health Solution category, will be presenting in San Francisco at the BioTech Showcase. HeartSciences has two scheduled presentations: (1) Tuesday, January 9 at the BioTech Showcase at 2:45pm at the Hilton Hotel, Union Square and (2) Wednesday, January 10 at the Digital Medicine and Technology Showcase at 10:00am, at the Parc 55 Hotel.

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease. Its MyoVista hsECG (high sensitivity ECG), is designed to significantly improve the sensitivity of a diagnostic electrocardiology device in detecting ischemic and structural heart disease at an early stage. Through the patented use of Continuous Wavelet Transform digital signal processing it measures the heart’s energy during its cardiac cycle. Recent clinical trials demonstrate MyoVista’s ability to detect cardiac dysfunction in the diastolic phase, which is known as Diastolic Dysfunction. The MyoVista hsECG, includes all the conventional information of a full featured 12-lead resting ECG plus new energy related informatics assisting in the early detection of heart disease.

HeartSciences was selected as a Fierce Innovation Award Finalist in December 2017 for its innovative, MyoVista® hsECG™ (high sensitivity ECG) device. Finalists were selected from a highly competitive list of innovators by a distinguished panel of judges. All applications were evaluated based on the following criteria: Competitive Advantage, Financial Impact/Value, Market Need, and Overall Innovation. Applicants with the top 3 scores in each category were selected as finalists. Life Sciences Edition 2017, is an awards program from the well-known e-publisher of FierceBiotech and FiercePharma.

About HeartSciences

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease. HeartSciences is bridging today’s “diagnostic gap” in cardiac care by developing new low-cost effective solutions that assist in identifying at-risk patients.

HeartSciences’ MyoVista® hsECG™ Cardiac Testing Device is a new 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Its patented signal processing method measures myocardial energy during the cardiac cycle. Proprietary informatics focus on abnormalities related to cardiac energy levels in addition to providing traditional ECG information.

In addition to the proprietary informatics, MyoVista hsECG also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms.

HeartSciences (formerly known as Heart Test Laboratories) is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit www.heartsciences.com.

Contacts
HeartSciences
Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com

Permalink : http://aetoswire.com/news/5310/en

Ghana Government Launches Instant Electronic ID Issuance with Entrust Datacard

 Entrust Datacard partners with Identity Management Systems (a subsidiary of Margins Group) to deliver first nationwide instant issuance in West Africa

MINNEAPOLIS-Thursday, January 4th 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- Entrust Datacard, a leading provider of trusted identity and secure transaction technology solutions, today announced its technology will be used by the government of Ghana — through a partnership with Identity Management Systems (IMS), a subsidiary of Margins Group — to instantly issue national identity cards to Ghanaian citizens.

In line with the directive from the Government of Ghana to roll out the National Identification System (NIS), the National Identification Authority (NIA) will be responsible for ID card registration and instant issuance across Ghana. The new “GhanaCard” meets all international requirements for identity documents, such as chip-embedded technology and biometric capabilities. This is the first nationwide instant issuance of eIDs in West Africa and the system will be deployed to 16 million citizens beginning in January 2018.

“Identity Management Systems designed a custom solution that fits Ghana’s economic and social needs, utilizing Entrust Datacard™ printers,” said Xavier Coemelck, regional vice president for Entrust Datacard EMEA. “Entrust Datacard technologies will enable the government of Ghana to improve service to its citizens and help ensure secure access to rights and services. This project demonstrates our ability to customize our solutions to fit all customer requirements.”

Using Entrust Datacard instant issuance technology, Identity Management Systems will support the National Identification Authority to facilitate mass registration of citizens throughout the country, promoting shorter travel and wait times for the new ID cards. Because the national ID cards are instantly issued, the government of Ghana will no longer have to manage the high quantity of personalized cards that are never picked up by citizens. The solution increases personalization and convenience in a government-to-citizen interaction.

“We are proud to introduce the first instant identity issuance in the region which improves the NIS experience for citizens and ensures social inclusion,” said Professor Ken Attafuah, Executive Secretary of NIA. “We are also grateful to our subcontractors who have helped us launch and facilitate the National Identification System.”

Identity Management Systems Ltd is the prime contractor for Ghana National ID project. With Entrust Datacard, the other subcontractors for the project include Intelligent Card Production Systems (ICPS), X-Infotech, Dermalog, Cryptovision, Smart Packaging Solutions (SPS), NXP Semiconductors and IDFG.

For more information on Entrust Datacard ID card printers, visit https://www.entrustdatacard.com/products/categories/id-card-printers.

About Entrust Datacard Corporation

Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure transaction technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates and secure communications. With more than 2,000 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com.

Contacts

Entrust Datacard
Heather Morris, +1 952-988-1745
Senior Manager, Global Communications
heather.morris@entrustdatacard.com

Permalink : http://aetoswire.com/news/5309/en

WayRay to Demo First Ever Holographic AR Navigation System with SDK Availability at CES 2018

LAUSANNE, Switzerland-Thursday, January 4th 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- WayRay, a Swiss developer of holographic AR navigation systems for cars, is coming to CES 2018 to demonstrate cutting-edge technologies:

-NAVION, the world’s first ever holographic AR navigator

-An advanced version of the embedded Holographic AR Display

-True AR SDK for Holographic AR Displays

-Element, a gamified car tracker for smarter driving

NAVION gets its first ever public showcase after 4 years of R&D. For OEMs, WayRay will demonstrate the new multicolored version of the world’s first holographic AR Infotainment System for cars. Following the first successful demo in the Rinspeed Oasis Car at CES 2017, this year we are proud to show off its newest version. It has an extremely wide field of view and even smaller projector's volume. For developers, WayRay will demo our True AR SDK and announce the AR Developers Contest & Hackathon with a total prize fund worth $160,000.

Where to find us: Booth # 26047 LVCC - South Hall 2.

NAVION — WayRay’s flagship device

NAVION is the first True Augmented Reality car navigation system. Placed on a dashboard, it shows directions, trip details and display real-time indicators for things like pedestrians, POIs or alerting to hazards exactly where the driver needs them to be — on the road ahead — with no headgear or eyewear required. NAVION is able to work in a hands-free mode to get the driver safely to the destination. It responds to the simple voice commands or to unique hand gestures.

AR infotainment system for connected cars

Another WayRay’s attraction at CES 2018 is a multicolored Holographic Augmented Reality display device designed to transform the windshield into a new medium of information. 2018’s version has the greatest FOV (field of view) on the market and is capable of multicolored virtual objects creation. Moreover, the technology allows the solution to act like a fully-featured non-wearable augmented reality infotainment system. It shows relevant information at a comfortable distance for users' eyes — from 3 ft to infinity.

True AR SDK

True AR SDK is a set of libraries and tools for third-party developers to build AR applications that run on Holographic AR Displays. The SDK also has the AR Holographic Display simulator, a tool for testing and debugging the behavior of the app content under different FOV and display locations, in various cars. True AR SDK runs on Ubuntu 16.04 and supports C++ and GLSL with binding to other programming languages.

ELEMENT – wearable for your car

Element is an insightful interactive tracker car tracker for smart driving. It tracks driver’s activity at the wheel and overviews the driving performance. That’s why we call it ‘a wearable for your car.’ Besides, Element has a unique feature known as Autoyoga, which adds an element of fun to the daily commute. Visitors can get familiar with a product and the app, and place a preorder.

About WayRay

WayRay is a global company headquartered in Switzerland, with 170+ engineers, its own R&D center and prototyping laboratory. It specializes in development and production of transparent holographic displays based on HOE (holographic optical elements) and commercialisation of this technology for consumer electronics and b2b markets. https://wayray.com/

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180103005559/en/

Contacts

WayRay
Mary Glazkova, +1 650 391-49-48
VP of Communications
mary@wayray.com | http://wayray.com


Permalink : http://aetoswire.com/news/5307/en

Masimo Announces CE Marking and Release of Oxygen Reserve Index™ rainbow Lite Sensors

NEUCHATEL, Switzerland-Tuesday, January 2nd 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the CE marking and release of RD rainbow Lite SET™ sensors, which enable the monitoring of Masimo Oxygen Reserve Index™ (ORi™) and RPVi™, an improved PVi® that allows clinicians to assess fluid responsiveness noninvasively and continuously1 at a fraction of the cost of invasive methods, and at a fraction of the cost of rainbow® sensors. rainbow Lite sensors utilize twice as many wavelengths of light as SET® sensors, allowing rainbow Lite sensors to provide ORi and RPVi along with Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry.

ORi is the first noninvasive and continuous parameter to provide insight into a patient’s oxygen reserve in the moderate hyperoxic range. In conjunction with SET® pulse oximetry, ORi may provide advanced warning of impending desaturation, which may allow clinicians to intervene sooner. For example, in a study of 25 pediatric patients undergoing general anesthesia with orotracheal intubation, researchers found that ORi helped clinicians identify impending desaturation a median of 31.5 seconds before noticeable changes in oxygen saturation (SpO2) occurred.2 In another recent study of 106 adult patients scheduled for surgery with arterial catheterization and intraoperative blood gases analyses, researchers found a significant relationship between change in PaO2 and change in ORi.3 In addition, ORi may provide insight into oxygen reserve when titrating patients who are receiving supplemental oxygen.4

Joe Kiani, Founder and CEO of Masimo, said, “rainbow Lite sensors allow clinicians, who depend on powerful SET® pulse oximetry technology, to augment their patient monitoring with ORi and newly introduced RPVi. Given the positive reception of ORi in available markets, and feedback from clinicians who see great value in the benefits of ORi monitoring, we are excited to make ORi and RPVi accessible via the cost-effective solution represented by RD rainbow Lite SET. Hospitals that standardize on RD rainbow Lite SET will pay only nominally more per sensor than for SET®.”

Masimo RPVi is a multi-wavelength version of Pleth Variability Index (PVi). RPVi is designed to provide enhanced assessment of changes in fluid volume compared to PVi5, which has been shown in over 90 independent clinical studies to be as effective as invasive monitoring methods.6

With the addition of RD rainbow Lite SET, the RD family of sensors is now available in three levels of capability: RD SET, utilizing two wavelengths (2 LED) and featuring SET® pulse oximetry; RD rainbow Lite SET, which utilizes four wavelengths (4 LED) and adds the ability to measure ORi and RPVi; and RD rainbow SET, which utilizes over seven wavelengths (7+ LED) and enables the measurement of additional advanced noninvasive parameters such as SpHb®(total hemoglobin), SpCO® (carboxyhemoglobin), SpMet® (methemoglobin), and SpOC™ (oxygen content).

Like RD SET sensors, RD rainbow Lite SET sensors are designed to maximize patient comfort and optimize clinician workflow. The sensors are lightweight and have a flat, soft cable with smooth edges, so that they lie comfortably on a patient’s hand or foot. The sensors feature an intuitive sensor-to-cable connection, with tactile and audible feedback to ensure a proper connection, and have graphics printed on both sides to assist with application.

Devices with ORi and RPVi measurements and RD rainbow Lite SET sensors have not received FDA 510(k) clearance and are not available for sale in the United States.

@MasimoInnovates | #Masimo

References

    Forget P, Lois F, de Kock M. Goal-Directed Fluid Management Based on the Pulse Oximeter-Derived Pleth Variability Index Reduces Lactate Levels and Improves Fluid Management. Anesth Analg. 2010 Oct; 111(4):910-4.
    Szmuk P, Steiner JW, Olomu PN, Ploski RP, Sessler DI, and Ezri T. Oxygen Reserve Index A Novel Noninvasive Measure of Oxygen Reserve—A Pilot Study. Anesthesiology. 4 2016, Vol. 124, 779-784. doi:10.1097/ALN.0000000000001009.
    Applegate R, Dorotta I, Wells B, Juma D, and Applegate P. The Relationship Between Oxygen Reserve Index and Arterial Partial Pressure of Oxygen During Surgery. Anesth Analg. 2016 Sep; 123(3); 626-633.
    Scheeren TWL, Belda FJ and Perel A. The oxygen reserve index (ORi): a new tool to monitor oxygen therapy. J Clin Monit Comput. 2017. doi:10.1007/s10877-017-0049-4.
    Masimo data on file.
    Published clinical studies on PVi can be found at http://www.masimo.com/en-GB/home/clinical-evidence/pleth-variability-index-pvi/.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 17 of the top 20 hospitals listed in the 2017-18 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

    Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb; 100(2):188-92.
    de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.
    Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
    Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
    McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul; 42(7):293-302.
    Estimate: Masimo data on file.
    http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo RD rainbow Lite SET™ sensors, ORi™, RPVi™, and PVi®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo RD rainbow Lite SET sensors, ORi, RPVi, and PVi, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180101005082/en/

Contacts

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com


Permalink : http://www.aetoswire.com/news/5303/en

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€

 • The Boehringer Ingelheim Venture Fund (BIVF) extends its investment focus to include regenerative medicine, infectious diseases and digital health

• BIVF increases its presence in the United States and adds new staff members

• Through its successful investments in immune-oncology, the BIVF has helped the company elevate its presence across the global healthcare ecosystem and establish a new focus area

INGELHEIM, Germany & BOSTON-Wednesday, January 3rd 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in promising early stage start-up companies, focusing on regenerative medicine, infectious diseases and immune oncology among others, as well as growing the portfolio in the U.S. and opening doors for the BIVF in digital health. The significant additional funding goes along with a doubling of the number of investment managers.

“We at the BIVF are inspired by the opportunity to increase investments and work across some of the most promising areas of biomedical research to date,” says Frank Kalkbrenner, M.D., Corporate Vice President and Head of the BIVF. “We are thrilled to be opening a second U.S.-based office in 2018, which will allow us to collaborate more closely with biotech and start-up companies on the West Coast. This also brings us one step closer in our quest to be at the centre of the global digital health transformation.”

The expansion builds on the BIVF’s existing portfolio of 21 biotech and early stage start-up companies focused on various therapeutic areas of interest, including immune-oncology. Recent successes of the portfolio include:

    Rigontec is a forerunner in accessing the retinoic acid-inducible gene I pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec was acquired by Merck (known as MSD outside of the U.S. and Canada) in September 2017, with an upfront payment of EUR 115 million and additional contingent payments of up to EUR 349 million.
    ViraTherapeutics specializes in the development of oncolytic virus therapies. In 2016, BIVF entered into an option agreement with a transaction value of up to EUR 210 million, including co-funding of development activities of ViraTherapeutics’s VSV-GP.
    Okairos is pioneering the development of T-cell based vaccines for major infectious diseases, as well as cancer. In 2011, one year after the BIVF was founded, the first investment was made in Okairos. The company was acquired by GlaxoSmithKline in 2013, creating the first successful exit for BIVF.

“The key differentiator for Boehringer Ingelheim’s Venture Fund lies in the close and trusted relationships with the portfolios and entrepreneurs with whom we are privileged to work with,” added Kalkbrenner. “Through these connections, we’ve successfully developed a number of biotech start-ups – from creation to exit – and we look forward to the ground-breaking work that lies ahead. We are a team that welcomes new adventure and risk-taking, if it means delivering novel solutions that will one day help patients everywhere lead healthier lives.”

Boehringer Ingelheim’s innovation strategy furthers its commitment to push the boundaries of biomedical research and development by accelerating the delivery of first in class breakthrough therapies for patients in need. The BIVF invests in the development of pioneering science, which offers the potential to provide significant benefits for patients, creating options for Boehringer Ingelheim to expand into new areas. It actively works to spin-out and create companies from academia, developing projects over a five to seven year time period with initial investments in seed or series A funding. Staged investments start with EUR 0.5-3 million and can amount to up to EUR 10-15 million in funding.



LINK Press Release:

http://www.boehringer-ingelheim.com/press-release/bivf-funding-more-doubled-250-m

Contacts

Boehringer Ingelheim Corporate Center GmbH
Dr. Reinhard Malin
Head of Communications Innovation Unit
Media + PR
P: +49 6132 77-90815 :: M: + 49 151 150 20 690
reinhard.malin@boehringeringelheim.com
or
Boehringer Ingelheim Pharmaceuticals, Inc.
Linda Ruckel
Associate Director, Media and Corporate Reputation
Ridgefield, Connecticut
P: +1 203 791-6672 :: M: +1 203-957-5114
linda.ruckel@boehringer-ingelheim.com


Permalink : http://aetoswire.com/news/5308/en

Age No Mark: Gregory Gaultier Makes It to Semifinals in Manchester

Gaultier, who turns 35 today played with outstanding dexterity in the contest

Dubai, United Arab Emirates -Thursday, December 28th 2017 [ AETOS Wire ]

‘Age is just a state of mind’. While for some, age marks the end of a career, Gregory Gaultier, the French top seed who was recently seen at the semifinals of the Squash World Champions believes in defying the conventional thinking. 

Despite losing the semifinals with Mohamed El Shorbagy, Gregory Gaultier, who turns 35 in a week's time and is short of sleep after the birth of his second son, played with outstanding dexterity in the first and third game and might have become a strong challenger if he had made it to the finals.

Dr. William Murrell, CEO of Emirates Integra Medical & Surgical Centre, an Emirates Healthcare company said, “Squash is one game which requires a lot of control and focus, and playing the game at the age of 35 at professional level is not kind of a story you hear a lot. Gregory has not only made it to the semi-finals, but has been a strong opponent for players a decade younger than him. This is truly inspirational and we’re proud that Gregory is the ambassador of goodwill and determination with Emirates Integra.”

Dr. William Murrell added, “The muscles mass, joints and bones have to be in good condition to play a sport as squash at this age, which is a clear reflection of a right pattern of lifestyle implemented by Gregory to maintain his incredible longevity at the top of squash for so many years. It emphasizes that using the right sport technique, agenda and with the advances in regenerative medicine like PRP, we can now help maintain players longer and more naturally. Gregory has maintained great discipline, and rigorous training to meet the sports great demands physically and mentally. “Maintenance is an essential step to not just a healthy living for the day, but also in the future.”

 “In my career spanning 15 years, I’ve seen young players who are barely in their early twenties, having body structure and strength like players much older. This is a result of several unhealthy habits with major causes being use of mobile, television and inadequate warm-up techniques,” concluded Dr. William Murrell.

Emirates Integra, trains professional players across varied sports, including Tennis, Martial Arts, Football, American Football, Basketball and Cricket among many. We use state-of-the-art technology and sophisticated techniques and procedures to determine the ideal treatment procedures that promotes healing and restores movement.


Contacts

SAHARA Communications

Reshmi S. Kumar, Project Coordinator, +97143298996, +971564232760

 reshmi@saharagcc.com



Permalink : http://aetoswire.com/news/5299/en

Emirates Healthcare Group partners with Egypt’s Alameda Healthcare

Abu Dhabi, United Arab Emirates.-Tuesday, January 2nd 2018 [ AETOS Wire ]

In a significant development for health care in the region, Emirates Healthcare Group has strategically partnered with Egypt’s Alameda Healthcare Group.

Alameda Healthcare Group, which has the largest healthcare footprint in Egypt that totals 860 beds, including both Dar El Fouad Hospital and As Salam International Hospital, in addition to chain of labs, tabibi 24/7 and GIT stand-alone units.

Emirates Healthcare Group, a leading global healthcare provider, is a part of Abu Dhabi-based investment group KBBO. Khalifa Bin Butti, Chairman of KBBO Group, hailed the partnership as a significant development for healthcare in Egypt and the region

“Our expansion in Egypt comes from our strong belief in the development and prosperity of the Egyptian market, and the progress that Egypt is making in all areas as a nation” Mr. Khalifa added.

“We’re excited to establish an extensive presence in the vibrant Egyptian market. It’s an important addition to our global healthcare network, further extending the reach of the highest standard patient care we provide globally to around eight million patient each year.”

Mr. Khalifa also noted the serious need for additional healthcare in Egypt.

“The population of Egypt has reached 91 million, yet the number of hospital beds available is less than two beds per 1,000 people. With an annual population growth of 2.2 per cent, Egypt desperately needs more hospital beds and improved quality of healthcare services, which this partnership will help provide.”

Dr. Fahad Khater who will manage and head the group in Egypt as chairman from Alameda Healthcare in addition to his role as Vice chairman of Emirates Healthcare Group will have a tremendous impact on both the quality and accessibility of healthcare in Egypt and part of the strategy going forward will be to increase our footprint in Egypt and the surrounding areas where we can reach and impact as many lives as possible.

“We’re delighted to have a strategic partner with the capabilities, international experience and authority in the healthcare sector of KBBO Group,” said Dr. Fahad

“We’re continually looking for ways to improve our facilities and the care we provide to patients, whether it’s through our new and recently-upgraded hospitals and medical complexes, or via international partnerships with healthcare specialists like Emirates Healthcare Group.

“There has been an increased quality of healthcare in Egypt in recent years, largely because of increased healthcare medical insurance and on-going investment in the sector from international companies like KBBO. Today’s partnership is not just with Alameda Healthcare Group but in Egyptian healthcare; it will enhance the quality of – and access to – healthcare for all Egyptians.

The partnership adds to Emirates Healthcare Group’s vast portfolio of health care services that includes hospitals and clinics located across the UAE and internationally, such NMC healthcare, Emirates Hospitals and CosmeSurge.

Contacts

Farah Al obaidi  

Head of Media Relations

Tel: +971 50 1714347     

Mob: +971 503323158

Email: farah@saharagcc.com

Permalink : http://aetoswire.com/news/5304/en